Curevo is a biotechnology company focused on developing vaccines with improved tolerability and accessibility, currently advancing a shingles vaccine called amezosvatein.

Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.

Abcuro, Inc. is a biotechnology company developing therapies for autoimmune diseases and cancer, with a focus on their lead candidate, ulviprubart, a monoclonal antibody for treating inclusion body myositis.

AdvanCell is a clinical-stage radiopharmaceutical company developing innovative cancer therapies using targeted alpha-emitting radionuclides.

Normunity is a biotechnology company developing anti-cancer therapies that target novel tumor-specific mechanisms to engage T cells and suppress immune evasion in solid tumors.

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Zucara Therapeutics Inc. is a life sciences company developing treatments to prevent hypoglycemia in diabetes patients.

Resalis Therapeutics is a biotechnology company developing an antisense oligonucleotide treatment for obesity by targeting metabolic pathways.

Agomab Therapeutics is a Belgian biotech company developing novel treatments for fibrosis, with a pipeline of growth factor targeting antibodies and small molecule compounds.

Nura Bio Inc. develops neuroprotective therapies for neurological diseases, with a focus on advancing their lead candidate, a brain-penetrant SARM1 inhibitor.

Sudo Biosciences is a biopharmaceutical company developing TYK2 inhibitor candidates for the treatment of multiple sclerosis, neurodegenerative, and immune-mediated dermatologic diseases.

Eligo Bioscience is a gene-editing biotech company focused on developing precision medicines for immuno-inflammation, oncology, and infectious diseases by leveraging microbiome in-vivo gene editing technologies.

T-Therapeutics is a biotech firm specializing in developing TCR therapeutics for cancer and inflammatory disorders using their proprietary OpTiMus® platform.

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.